

Date: 1st February, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In continuation to our earlier communication dated 4th October, 2023 and 5th January, 2024 regarding disruption of business operations at the Company's manufacturing facilities at Namthang, South Sikkim and updates on the same, respectively, we would like to inform that the Company has commenced operations in a phased manner and expect the facility to be fully operational within a month.

We shall intimate to the Stock Exchanges once the normalcy of operations is restored.

The details as required under Regulation 30 of SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 are enclosed herewith and marked as Annexure – 'A'.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

Annexure – ‘A’

Details as required under Regulation 30 of SEBI Listing Regulations read with Circular no SEBI/HO/CFD-PoD-1/P/CIR2023/123 dated 13th July 2023:

Sr. No.	Particulars	Details
i)	Insurance amount claimed and realized by the listed entity for the loss/damage;	The Company is in discussion with Insurance Companies as well as with surveyors appointed by the Insurance Companies to arrive at the final amount of loss.
ii)	The actual amount of damage caused due to the natural calamity or other force majeure events;	<p>In the meantime, the Company has estimated and recognized an initial loss of Rs. 45.32 crores and has received Rs. 30 crores as reimbursement in the interim settlement, which was intimated vide our communication dated 5th January, 2024 and another Rs. 15 crores up to the current date, totaling to Rs. 45 crores towards the Company's claim against damages of certain property, plant & equipment and inventory.</p>
iii)	Details of steps taken to restore normalcy and the impact of the natural calamity/ other force majeure events on production or service, financials of the entity;	Please refer our earlier communication dated 5 th January, 2024.

ALEMBIC PHARMACEUTICALS LIMITED